Bruker Corporation
BRKR
NASDAQ62.73
Bruker Corporation
NASDAQ:BRKR
RECENT
PRICE
62.73
P/E
RATIO
33.81
(PEG:0.45)
P/E RATIO
RELATIVE
TO S&P
1.63
DIV
YLD
0.23%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
1.25 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 06/22:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
4.29
0.18
0.30
- -
5.28
0.30
0.12
- -
6.80
0.40
0.37
0.14
6.82
0.50
0.82
- -
7.94
0.58
0.76
0.00
9.99
0.56
0.20
- -
10.79
0.47
0.36
- -
11.05
0.48
0.57
- -
10.78
0.34
0.48
- -
9.65
0.60
1.16
- -
9.98
0.95
0.58
0.16
11.17
0.50
0.70
0.16
12.14
1.15
1.22
0.16
13.35
1.27
0.90
0.16
12.96
1.03
1.53
0.16
15.76
1.81
1.24
0.16
16.27
1.87
1.16
0.17
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.08
1.89
0.16
2.49
0.29
1.92
0.10
2.55
0.19
3.19
0.33
3.76
0.44
4.26
0.30
5.08
0.20
4.56
0.20
4.32
0.23
4.25
0.28
4.59
0.31
5.74
0.47
5.84
0.63
6.27
0.60
7.07
0.57
6.91
CAPEX per share
Book Value per share
102
104
163
164
164
165
166
167
168
168
161
158
156
155
153
153
151
Comm.Shares outs.(m)
33.0
1.8
- -
30.0
1.7
- -
28.7
1.3
1.3%
16.5
0.2
- -
23.8
1.1
0.0%
29.9
1.8
- -
29.7
2.0
- -
37.9
2.2
- -
62.7
3.5
- -
32.6
1.6
- -
25.3
1.1
0.7%
56.0
2.4
0.6%
27.7
1.1
0.5%
33.5
1.4
0.4%
42.4
1.1
0.4%
40.4
1.3
0.2%
33.8
1.6
0.2%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/3/22 | Q1)
Total liabilities
$2,519 m.
Total assets
$3,551 m.
Long-term debt
$1,205 m.
Cash and equiv.
$816 m.
Goodwill $384 m.
Retained earnings - -
Common stock 150 m. shares
Market Capitalisation
$9,336 m. (as of 29/6/22)
1,652
9.4%
1,791
8.7%
1,839
8.1%
1,809
5.8%
1,624
9.0%
1,611
11.0%
1,766
12.2%
1,896
13.8%
2,073
14.5%
1,988
12.5%
2,418
17.1%
2,458
17.0%
Revenue (m)
Operating margin
3
92
59
78
61
80
60
57
53
102
54
154
64
79
65
180
76
197
80
158
89
277
89
282
Depreciation (m)
Net profit (m)
35.4%
5.6%
43.5%
4.3%
34.3%
4.4%
41.2%
3.1%
18.0%
6.3%
13.0%
9.5%
59.4%
4.5%
26.0%
9.5%
29.4%
9.5%
28.5%
7.9%
28.7%
11.5%
29.0%
11.5%
Income tax rate
Net profit margin
438
219
622
628
336
707
783
354
846
784
354
766
677
266
726
751
392
686
834
416
725
705
323
897
1,151
813
907
1,133
842
961
1,533
1,222
1,085
1,370
1,205
1,017
Working capital (m)
Long-term debt (m)
Equity (m)
10.3%
8.9%
14.9%
7.3%
8.2%
11.0%
6.7%
6.9%
9.5%
5.1%
6.0%
7.4%
9.6%
8.0%
14.0%
12.9%
10.5%
22.4%
6.1%
10.9%
10.8%
12.5%
12.1%
20.0%
9.9%
10.7%
21.7%
7.5%
7.8%
16.4%
10.3%
10.7%
25.5%
10.8%
11.4%
27.7%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
685
688
1,075
Receivables
362
335
417
Inventory
577
692
710
Other
172
166
177
Current assets
1,796
1,925
2,472
Acc. Payable
118
135
147
Debt due
21
24
112
Other
506
634
679
Current liab.
646
792
939
100.0%
(9.9)%
100.0%
(7.5)%
100.0%
(8.7)%
100.0%
(9.8)%
100.0%
40.6%
83.2%
186.0%
67.7%
142.4%
86.0%
8.2%
87.3%
111.4%
84.4%
61.5%
91.3%
89.5%
90.9%
138.0%
Plowback ratio
Div.&Repurch. to FCF
Bruker Corporation (US) started trading on August 5, 2000 (cik: 0001109354), operates in the Healthcare sector (Medical Devices industry), has 7,765 full-time employees, and is led by Dr. Frank Laukien. Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
8.56%
3.76%
Cash flow
23.55%
27.19%
Earnings
48.50%
27.74%
Dividends
-1.20%
- -
Book value
10.89%
5.43%
Insider trading
Type
Shares
Date
Laukien Frank H
Purchase
1,710
05/11/22
Ma Philip
Award
1,616
04/01/22
Laukien Frank H
Exempt
40,490
02/18/22
Laukien Frank H
Sale
26,790
02/18/22
Laukien Frank H
Exempt
40,490
02/18/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
424
425
511
628
1,988
2021
555
571
609
684
2,418
2022
595
- -
- -
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
0.07
0.16
0.35
0.45
1.03
2021
0.37
0.38
0.57
0.49
1.81
2022
0.41
- -
- -
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
0.04
0.04
0.04
0.04
0.16
2021
0.04
0.04
0.04
0.04
0.16
2022
0.05
- -
- -
- -
- -